Notes:
The Anticoagulants in the Secondary
Prevention of Events in Coronary Thrombosis (ASPECT) trial
(1994) was a randomized, placebo-controlled, double-blind,
trial of 3404 p-MI pts.
Pts rec’d either placebo or anticoagulant
(nicoumalone or phenprocoumon) adjusted to an INR of 2.8–4.8
and were followed for an avg of 3 yrs.
Reinfartion was decreased:53%
Nonfatal stroke was decreased:40%
Death was decreased:10%
Major Hemorrhage was was increased:
280% (a factor of 3.8).
Per 100 which we intend to Tx w/
anticoagulant instead of placebo we would:
- prevent: 3 MI’s, 0.5 CNS events (including ICB), 0.4
deaths
- cause: 1 major (nonfatal) bleed
|
Stroke Education
